Losartan blocks the angiotensin II type 1 (AT1) receptor, reducing aldosterone secretion, lowering peripheral vascular resistance, and decreasing sodium reabsorption in the proximal tubule [1]
The risk of developing PD increases with age significantly, impacting roughly 1% of individuals over 60 and as many as 4% of those aged 80 or older 34
Important stacking considerations More peptides don't automatically mean better results
People who are joining the Wegovy MDL have: Taken a GLP-1 RA drug, such as Wegovy, as directed and prescribed Experienced a serious adverse health event that either wasnt listed on the label or that they were not appropriately warned about Recognized that the drugs manufacturer didn't advertise potential side effects The lawsuits in the MDL have named drug makers Novo Nordisk and Eli Lilly as defendants
The significant GI side effects, major fueling challenges, risk of muscle loss (and lost watts), high cost, and questionable long-term impacts should give any rider pause
Provider-determined dose and application cadence